Clinical Trials | October 30, 2023
SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The companies plan to start a pivotal Phase 3 trial in the coming months
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Subscribe To Our Newsletter & Stay Updated
